Cobimetinib: all 92 studies that test it
Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaRecruitingNCT07449754Phase 2
- Using Tumor Models to Determine TreatmentsRecruitingNCT06813079Phase 2
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingNCT06440850Phase 2
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/3
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingNCT04302025Phase 2
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersRecruitingNCT04079179Phase 2
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingNCT04005690Early Phase 1
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
- Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract CancerActive, not recruitingNCT04941287Phase 2Results posted
- Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway MutationsActive, not recruitingNCT04409639Phase 2Results posted
- Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced MalignanciesTerminatedNCT04214418Phase 1/2Results posted
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/2Results posted
- Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive, not recruitingNCT03600701Phase 2Results posted
- Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerTerminatedNCT03566485Phase 1/2Results posted
- Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III MelanomaCompletedNCT03554083Phase 2Results posted
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedNCT03281369Phase 1/2Results posted
- A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type MelanomaTerminatedNCT03273153Phase 3Results posted
- Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaActive, not recruitingNCT03224767Phase 2Results posted
- Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder CancerCompletedNCT03201458Phase 2Results posted
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedNCT03193190Phase 1/2Results posted
- Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaCompletedNCT03178851Phase 1Results posted
- Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsCompletedNCT03108131Phase 2Results posted
- A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)CompletedNCT02788279Phase 3Results posted
- Single-agent Cobimetinib for Adults With Histiocytic DisordersCompletedNCT02649972Phase 2Results posted
- Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid TumorsCompletedNCT02639546Phase 1/2Results posted
- A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT02457793Phase 1Results posted
- A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has SpreadTerminatedNCT02322814Phase 2Results posted
- A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver DamageCompletedNCT02300025Phase 1Results posted
- A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)CompletedNCT02291289Phase 2Results posted
- Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain MetastasesTerminatedNCT02230306Phase 2Results posted
- My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
- A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy ParticipantsCompletedNCT01929876Phase 1Results posted
- The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With MelanomaTerminatedNCT01813214Phase 2Results posted
- A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaCompletedNCT01689519Phase 3Results posted
- A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01562275Phase 1Results posted
- Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaTerminatedNCT01495988Phase 2Results posted
- A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy ParticipantsCompletedNCT01277718Phase 1Results posted
- A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic MelanomaCompletedNCT01271803Phase 1Results posted
- A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy ParticipantsCompletedNCT01249131Phase 1Results posted
- An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)CompletedNCT01249118Phase 1Results posted
- Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid TumorsTerminatedNCT00996892Phase 1Results posted
- T3011 in Combination With Cobimetinib in Patients With Advanced MelanomaSuspendedNCT05756556Phase 2
- Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingNCT05691504Phase 1
- Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT05441514Phase 1
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)CompletedNCT05125471Phase 2
- Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic CancerCompletedNCT05034627Phase 1
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
- A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingNCT04835805Phase 1
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2
- MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue SarcomaCompletedNCT04216953Phase 1/2
- A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2
- Cobimetinib for BRAF-wild-type or Mutated HistiocytosesCompletedNCT04007848Phase 3
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
- Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
- Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain MetastasesTerminatedNCT03430947Phase 2
- Pre-operative Immunotherapy Combination Strategies in Breast CancerCompletedNCT03395899Phase 2
- BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
- Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal CancerWithdrawnNCT03340558Phase 2
- HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03284502Phase 1
- Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma PatientsTerminatedNCT03224208Phase 2
- A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCActive, not recruitingNCT03202940Phase 1/2
- Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerActive, not recruitingNCT03202316Phase 2
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
- Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain MetastasesActive, not recruitingNCT03175432Phase 2
- ML29255 Neoadjuvant Vemurafenib and Cobimetinib MelanomaWithdrawnNCT03005639Phase 2
- Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyStatus unknownNCT02968303Phase 2
- Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902029Phase 2
- Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other TumorsCompletedNCT02876224Phase 1
- Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced MelanomaTerminatedNCT02818023Phase 1
- A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced MelanomaCompletedNCT02768207Phase 2
- XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaActive, not recruitingNCT02721459Phase 1
- A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic TherapyCompletedNCT02670044Phase 1
- Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic MelanomaCompletedNCT02583516Phase 2
- Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant MelanomaWithdrawnNCT02427893Phase 3
- Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTerminatedNCT02303951Phase 2
- A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule FormulationCompletedNCT02136524Phase 1
- Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node MetastasesStatus unknownNCT02036086Phase 2
- Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01988896Phase 1
- A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRASCompletedNCT01986166Phase 1
- Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer PatientsWithdrawnNCT01974258Phase 1
- Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF MutationCompletedNCT01959633Phase 1/2
- Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus CobimetinibTerminatedNCT01876641Phase 1
- A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male VolunteersCompletedNCT01711762Phase 1
- A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic MelanomaCompletedNCT01656642Phase 1